Reconstructing the human hematopoietic niche in immunodeficient mice: opportunities for studying primary multiple myeloma by Richard W. J. Groen, Willy.

Slides:

Advertisements

Similar presentations

Allo-HLA reactivity of virus-specific memory T cells is common by Avital L. Amir, Lloyd J. A. D'Orsogna, Dave L. Roelen, Marleen M. van Loenen, Renate.

Advertisements

A lower risk of recurrent venous thrombosis in women compared with men is explained by sex-specific risk factors at time of first venous thrombosis in.

Increased peripheral platelet destruction and caspase-3– independent programmed cell death of bone marrow megakaryocytes in myelodysplastic patients by.

Treosulfan-based conditioning regimens for hematopoietic stem cell transplantation in children with primary immunodeficiency: United Kingdom experience.

MicroRNA-34a expression correlates with MDM2 SNP309 polymorphism and treatment-free survival in chronic lymphocytic leukemia by Daniela Asslaber, Josefina.

Extracellular matrix protein tenascin-C is required in the bone marrow microenvironment primed for hematopoietic regeneration by Ayako Nakamura-Ishizu,

Clinical regressions and broad immune activation following combination therapy targeting human NKT cells in myeloma by Joshua Richter, Natalia Neparidze,

Stimulated Gene Expression Profiles as a Blood Marker of Major Depressive Disorder Sabine Spijker, Jeroen S. Van Zanten, Simone De Jong, Brenda W.J.H.

Granulocyte colony-stimulating factor enhances bone tumor growth in mice in an osteoclast-dependent manner by Angela C. Hirbe, Özge Uluçkan, Elizabeth.

New criteria for response assessment: role of minimal residual disease in multiple myeloma by Bruno Paiva, Jacques J. M. van Dongen, and Alberto Orfao.

Generating AML-Specific Peripheral Blood Autologous Cytotoxic T-Lymphocytes (CTLs)‏ by Rohtesh S. Mehta, Xiaohua Chen, Antony Jeyaraj, and Paul Szabolcs.

Pathogenesis beyond the cancer clone(s) in multiple myeloma by Giada Bianchi, and Nikhil C. Munshi Blood Volume 125(20): May 14, 2015 ©2015 by.

Cerebral Small Vessel Disease In Patients With Sickle Cell Disease: Initial Findings With Ultra-High Field 7T MRI by Veronica van der Land, Jaco J.M. Zwanenburg,

by Paul A. Carpenter, Meei-Li Huang, and George B. McDonald

Cytomegalovirus Status and the Outcome of T Cell–Replete Reduced-Intensity Allogeneic Hematopoietic Stem Cell Transplantation Frans M. Verduyn Lunel,

Donor versus no-donor comparison of newly diagnosed myeloma patients included in the HOVON-50 multiple myeloma study by Henk M. Lokhorst, Bronno van der.

Do HSCs divide asymmetrically?

Comparable results of umbilical cord blood and HLA-matched sibling donor hematopoietic stem cell transplantation after reduced-intensity preparative regimen.

Neoplastic blood cells become pluripotent

Evidence for the involvement of a hematopoietic progenitor cell in systemic mastocytosis from single-cell analysis of mutations in the c-kit gene by A.

by Masako Moriuchi, Hiroyuki Moriuchi, and Anthony S. Fauci

TCR-MHC-peptide(s): in vivo veritas

Multiple Myeloma: Interleukin-15 Antagonizes Bone Morphogenetic Protein-Induced Apoptosis and Growth Inhibition. by Magne Rekvig, Anne-Tove Brenne, Torstein.

Minimal Residual Disease Measurement By Deep Sequencing Reflects Changes In Disease Load During Therapy In Diffuse Large B Cell Lymphoma Patients by Nina.

Positioning NK-κB in multiple myeloma

An endothelial metronome breast cancer?

by Pieternella S. in `t Anker, Sicco A

Retroviral and Chemical Mutagenesis Identifies Pax5 as a Tumor Suppressor in B-Progenitor Acute Lymphoblastic Leukemia by Jinjun Dang, Charles G Mullighan,

A Clinical Evaluation of the International Lymphoma Study Group Classification of Non-Hodgkin's Lymphoma Blood Volume 89(11): June 1, 1997 ©1997.

T-cell epitopes within the complementarity-determining and framework regions of the tumor-derived immunoglobulin heavy chain in multiple myeloma by Lotta.

by Zhenping Zhu Blood Volume 108(6): September 15, 2006

BTK inhibition in myeloma: targeting the seed and the soil

Continuous in vivo infusion of interferon-gamma (IFN-γ) enhances engraftment of syngeneic wild-type cells in Fanca–/– and Fancg–/– mice by Yue Si, Samantha.

The Hematopoietic Stem Cell Transplant Comorbidity Index (HCT-CI) Can Predict for Readmission Following Autologous Stem Cell Transplant for Lymphoma and.

How I treat elderly patients with myeloma

Volume 14, Issue 2, Pages (January 2016)

by Thomas Rasmussen, Linda Jensen, Lone Honoré, and Hans Erik Johnsen

Nonmyeloablative conditioning for relapsed follicular lymphoma

Superior Survival after Autologous vs

Irreversible myelosuppression after fludarabine-melphalan conditioning: observations in patients with graft rejection by Koen Van Besien, Sonali Smith,

Molecular remission after myeloablative allogeneic stem cell transplantation predicts a better relapse-free survival in patients with multiple myeloma.

Plerixafor and G-CSF versus placebo and G-CSF to mobilize hematopoietic stem cells for autologous stem cell transplantation in patients with multiple myeloma.

SOX11 holds mantle cell lymphoma’s key to home

Functional neutrophils from human ES cells

627. Non-Invasive, Multimodal Imaging of Microvesicles with Metabolically Biotinylated, Membrane-Bound Gaussia Luciferase Molecular Therapy Volume.

by Jonathan N. Hofmann, Linda M. Liao, Michael N

Long-term follow-up of allogeneic hematopoietic stem-cell transplantation with reduced-intensity conditioning for patients with chronic myeloid leukemia.

by Lewis Hsu, Bhalchandra Diwan, Jerrold M. Ward, and Constance T

In Utero Depletion Of Fetal Host Hematopoietic Stem Cells Improves Engraftment Following Neonatal Transplantation In Mice by Chris Derderian, Charmin King,

Setting the table for macrophages

by Douglas D. Ross, Judith E. Karp, Tar T. Chen, and L. Austin Doyle

Accurate quantification of minimal residual disease at day 15, by real-time quantitative polymerase chain reaction identifies also patients with B-precursor.

by Paul A. Carpenter, Meei-Li Huang, and George B. McDonald

Bone Turnover Biomarkers Are Useful In Monitoring Myeloma Bone Disease and As Early Predictor Biomarkers For Relapse Disease In Multiple Myeloma by Kay.

Consensus strategy to quantitate malignant cells in myeloma patients is validated in a multicenter study by Peter Willems, Onno Verhagen, Christine Segeren,

Hematopoietic Stem Cell Transplantation after Reduced Intensity Conditioning in Acute Myelogenous Leukemia Patients Older Than 40 Years Cynthia Huisman,

Volume 25, Issue 8, Pages (August 2017)

by Santosh L. Saraf, Xu Zhang, Tamir Kanias, James P. Lash, Robert E

by Hannah L Bader, Tracy Pritchett, and Tien Hsu

Systemic inflammation induces release of cell-free DNA from hematopoietic and parenchymal cells in mice and humans by Anne Jan van der Meer, Anna Kroeze,

by Mieke Aldenhoven, Brigitte T. A. van den Broek, Robert F

Changes throughout time in the lineage content of clones regenerated in secondary mice. Changes throughout time in the lineage content of clones regenerated.

Erratum in Ledru et al. Alteration of tumor necrosis factor–α T-cell homeostasis following potent antiretroviral therapy: contribution to the development.

The natural history of respiratory syncytial virus infection in cancer and transplant patients: implications for management by Elias J. Anaissie, Tahsine.

Mesenchymal Stem Cell-Derived Vesicles Reverse Hematopoietic Radiation Damage by Sicheng Wen, Laura R Goldberg, Mark S Dooner, John L Reagan, and Peter.

Pure red cell aplasia by Robert T. Means Blood

Initial treatment of CLL: integrating biology and functional status

by Victor A. Chow, Mazyar Shadman, and Ajay K. Gopal

Cold agglutinin disease

New concepts for anticoagulant therapy in persons with hemophilia

Presentation transcript:

Reconstructing the human hematopoietic niche in immunodeficient mice: opportunities for studying primary multiple myeloma by Richard W. J. Groen, Willy A. Noort, Reinier A. Raymakers, Henk-Jan Prins, Linda Aalders, Frans M. Hofhuis, Petra Moerer, Jeroen F. van Velzen, Andries C. Bloem, Berris van Kessel, Henk Rozemuller, Ellen van Binsbergen, Arjan Buijs, Huipin Yuan, Joost D. de Bruijn, Michel de Weers, Paul W. H. I. Parren, Jan Jacob Schuringa, Henk M. Lokhorst, Tuna Mutis, and Anton C. M. Martens Blood Volume 120(3):e9-e16 July 19, 2012 ©2012 by American Society of Hematology

Artificial humanized bone microenvironment acts as a natural hematopoietic niche. Richard W. J. Groen et al. Blood 2012;120:e9-e16 ©2012 by American Society of Hematology

Humanized mice allow engraftment and growth of primary MM cells. Richard W. J. Groen et al. Blood 2012;120:e9-e16 ©2012 by American Society of Hematology

Engraftment of pMM cells in humanized mice coincides with osteolysis. Richard W. J. Groen et al. Blood 2012;120:e9-e16 ©2012 by American Society of Hematology

Primary MM cells can be luciferase gene marked, which allows real-time analysis of pMM cell growth. Richard W. J. Groen et al. Blood 2012;120:e9-e16 ©2012 by American Society of Hematology

BLI allows visualization of therapy in pMM-bearing mice. Richard W. J. Groen et al. Blood 2012;120:e9-e16 ©2012 by American Society of Hematology